Jinzhu Hu, Jianhua Yu, Qi Chen, Jianxin Hu, Qianghui Huang, Zhen Xia, Zirong Xia, Zhenzhen Ju, Ping Yuan, Siyang Fan, Qinmei Xiong, Bo Zhu, Lin Huang, Chunjiao You, Huihui Bao, Yanqing Wu, Xiaoshu Cheng, Juxiang Li, Ali J Marian, Kui Hong
Background The efficacy of nifekalant in preexcited atrial fibrillation ( AF ) has not been assessed. Methods and Results The study populations consisted of patients with sustained preexcited AF (n=51), paroxysmal supraventricular tachycardia (n=201), and persistent AF (n=87). Effects of intravenous infusion of nifekalant were assessed on electrophysiological and clinical parameters. Nifekalant prolonged the shortest preexcited R-R, the average preexcited R-R, and the average R-R intervals from 290±35 to 333±44 ms, 353±49 to 443±64 ms, and 356±53 to 467±75 ms, respectively, in patients with preexcited AF (all P<0...
July 2, 2019: Journal of the American Heart Association